Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Overview
Date Founded

2007

Headquarters

88 Sidney Street,Cambridge, MA 02139-4169

Type of Company

Public

Employees (Worldwide)

562

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Agios Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Founder

Chief Executive Officer

Chief Commercial Officer

Chief Scientific Officer

Chief Scientific Officer

Chief People Officer

Chief Medical Officer

Board of Directors

General Partner at Google Ventures

Chief Executive Officer at Agios Pharmaceuticals, Inc.

Co-Founder at Fate Therapeutics, Inc.

Senior Advisor at The Boston Consulting Group, Inc.

Former Senior Vice President of Finance at Biogen MA, Inc.

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Venture Partner Healthcare at Qiming Venture Partners Ltd.

Operating Partner at Clarus Ventures LLC

Paths to Agios Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Agios Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

OrbiMed Advisors generally seeks long-term capital appreciation through investments in companies in the global healthcare industry. They utilizes strategies based on evaluating pharmaceutical, biotechnology, medical device, healthcare services and other companies in the global healthcare sector. The instruments in which OrbiMed invests include US and non-US equities, both long and short, as well as privately placed securities, debt securities, royalty bonds and other royalty instruments, currencies, private investments in public equity securities (PIPEs), ETFs, index options, and derivatives (including swap agreements). The firm employs a disciplined investment style and achieves diversification within the global healthcare sector, with the goal of creating attractive risk-adjusted returns.

Details Hidden

Rock Springs’ funds aims to generate capital appreciation through investments in a combination of public and private securities of companies in healthcare and healthcare-related industries. The funds focus mostly on public equities, utilizing a long-term, research-intensive approach to investing in healthcare and healthcare-related industries, with a particular emphasis on those companies and/or products that Rock Springs believes serve critical unmet needs.

Recent Transactions
Details Hidden

Agios Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Agios Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Agios Pharmaceuticals, Inc. issued . USD Common Stock

Insider Transactions
Details Hidden
Transaction Advisors
Escrow Agent

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAgios Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Advisor

Assurance Partner at Ernst & Young LLP

Advisor

Chief Scientific Officer at Agios Pharmaceuticals, Inc.

Clients

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. It offers cancer therapeutics with a special focus on immuno-oncology based combination therapies. The company was founded on December 2, 2015 and is headquartered in Shanghai, China.

Key Stats and Financials As of 2020
Market Capitalization
$3.68B
Total Enterprise Value
$2.52B
Earnings Per Share
$-4.74
Revenue
$203M
Net Profit
$-327M
EBITDA
$-297M
Total Equity
$400M
EBITDAMargin
-146.25%
Enterprise Value / Sales
12.41x
TEVNet Income
-7.7x
Total Debt
$105M
Debt TEV
0.04x
Three Year Compounded Annual Growth Rate Of Revenue
67.79%
Non-Profit Donations & Grants
$500 +
2019
$10K - $50K
2018
Investors
Details Hidden

Third Rock Ventures invests in companies located in the US. The firm targets operating in the fields of healthcare sector. It provides financing for early-stage capital requirements. It also acts as a lead investor.

Details Hidden

AECOM is a global provider of professional technical and management support services to a broad range of markets, including transportation, facilities, environmental, energy, water and government. With approximately 45,000 employees around the world, AECOM is a leader in all of the key markets that it serves. AECOM provides a blend of global reach, local knowledge, innovation and technical excellence in delivering solutions that create, enhance and sustain the world's built, natural and social environments

Details Hidden

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Suppliers
Foundation Medicine, Inc. Medical Support Services | Cambridge, MA

Foundation Medicine, Inc. is a molecular information company, which engages in the provision of information on clinical treatment decisions for patients with cancer. The company was founded by Alexis Borisy in 2010 and is headquartered in Cambridge, MA.

Forest City Realty Trust, Inc. Trusts & Funds | Cleveland, OH

Forest City Realty Trust, Inc. engages in the provision of real estate investment. Its activities include ownership, development, management, and acquisition of commercial and residential real estate throughout the United States. The firm's project portfolio consists of apartment properties, build-to-suit buildings, and regional and urban retail centers. The company was founded by Charles Ratner, Max, Ratner, Leonard Ratner and Fannye Ratner in 1920 and is headquartered in Cleveland, OH.

Dr Reddy's Laboratories Ltd. Medical Support Services | Hyderabad, India

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

BeiGene Ltd. Pharmaceuticals - Beijing, China

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Awards & Honors
2014
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Agios Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Agios Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Agios Pharmaceuticals, Inc..